Head-to-head · WeighScore
CoreAge Rx vs Lttl
By GLP-1 ScorecardUpdated
Score comparison
CoreAge Rx has the higher recorded score — 89.5/100 to 63.5/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
CoreAge Rx scores 89.5/100 (B+).
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoreAge Rx | Lttl |
|---|---|---|
| WeighScore | 89.5/100 | 63.5/100 |
| Grade | B+ | C |
| Site position | #1 | #209 |
| Semaglutide | Product page from $79/mo; navigation $99. Confirm selected quote. | $99/mo monthly auto-refill; $89/mo equivalent billed $1,068 annually (confirm supply/renewal) |
| Tirzepatide | From $129/mo advertised; confirm selected charge, supply and renewal. | $149/mo monthly auto-refill; $139/mo equivalent billed $1,668 annually (confirm supply/renewal) |
| Coverage | US only; therapy-specific state restrictions apply | Provider claims 50 states + DC; treatment availability varies |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Site position #1 · B+
Strengths
- Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
- Advertises the same price across doses and no membership fee
- Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy
What to consider
- Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
- FAQ no-rebill and payment-timing statements differ from the subscription and order policy
- FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
- Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
- Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Site position #209 · C
Strengths
- Public ordinary monthly injection rates of $99 semaglutide and $149 tirzepatide, with longer-plan charges disclosed separately
- The plan selector identifies supply lengths, including four weeks for monthly auto-refill and 52 weeks annually
- Four possible dispensing pharmacies are named in the terms, without an individual assignment established
- Microdose injection and oral-tablet selector entries provide additional options to discuss with a clinician; availability and clinical suitability require confirmation
What to consider
- Monthly, quarterly and six-month supply labels do not align with calendar-month language; confirm actual refill and debit intervals
- Medical-rejection refund language conflicts with consultation-fee retention wording
- Terms use medical intake as a nonrefund boundary, while support uses pharmacy processing/shipping; refund deadlines also differ
- The assigned treating practice, prescriber and actual dispensing location remain unestablished
- Branded-service exceptions are described, but no available brand-specific prescription or price was established
- A 48-hour shipping headline differs from the policy estimate of two to five business days processing plus three to seven in transit
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.